Form 8-K

8-K — Allarity Therapeutics, Inc.

Accession: 0001213900-26-070382

Filed: 2026-06-22

Period: 2026-06-18

CIK: 0001860657

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — ea0295409-8k_allarity.htm (Primary)

EX-99.1 — PRESS RELEASE, DATED JUNE 18, 2026 (ea029540901ex99-1.htm)

GRAPHIC (ea029540901_ex99-1img1.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0295409-8k_allarity.htm · Sequence: 1

false

0001860657

2026-06-18

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities

Exchange Act of 1934

Date of Report (Date of earliest event reported)

June 18, 2026

ALLARITY THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-41160

87-2147982

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

123 E Tarpon Ave,

Tarpon Springs, FL 34689

(Address of principal executive offices)

(401) 426-4664

(Registrant’s telephone number, including

area code)

Not applicable

(Former name or former address, if changed since

last report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b)

of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

ALLR

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Matters.

On June 22, 2026, Allarity Therapeutics, Inc.

(the “Company”) announced its presentation of a Trial-in-Progress poster at the ESMO Gynaecological Cancers Congress 2026,

which was held June 17–19, 2026, in Copenhagen, Denmark. A copy of the Company’s press release is attached hereto as Exhibit

99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

Number

Description

99.1

Press Release, dated June 18, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements

of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto

duly authorized.

Allarity Therapeutics, Inc.

Date: June 22, 2026

By:

/s/ Thomas H. Jensen

Thomas H. Jensen

Chief Executive Officer

EX-99.1 — PRESS RELEASE, DATED JUNE 18, 2026

EX-99.1

Filename: ea029540901ex99-1.htm · Sequence: 2

Exhibit 99.1

Allarity Therapeutics

to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026

Principal Investigator Kathleen N. Moore, M.D., a leading expert in advanced ovarian cancer, will present the poster

TARPON SPRINGS, Fla., June 18, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ:

ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and

WNT pathway inhibitor— today announced that it will present a Trial-in-Progress poster at the ESMO Gynaecological Cancers Congress

2026, held June 17–19 in Copenhagen, Denmark.

The poster outlines the scientific background, study design,

and clinical rationale for the Company’s ongoing Phase 2 trial evaluating stenoparib in patients with advanced platinum-resistant

or platinum-ineligible ovarian cancer. The study builds directly on Allarity’s prior Phase 2 clinical experience, including the

durable clinical benefit observed in heavily pretreated ovarian cancer patients. As a Trial-in-Progress presentation, the poster describes

the study design and clinical rationale but cannot include new clinical data.

The poster will be presented by the study’s Principal

Investigator, Kathleen N. Moore, M.D., an internationally recognized specialist in gynecologic oncology and a leading expert in advanced

platinum-resistant and platinum-refractory ovarian cancer. Dr. Moore is also a featured speaker during the congress, which brings together

leading international clinical investigators focused on advancing treatment for patients with gynecological cancers.

Poster presentation

● Title:

166TiP – NCT03878849: A phase II trial of stenoparib/2X-121, a novel dual inhibitor of PARP and the WNT pathway, in platinum resistant/ineligible

ovarian cancer patients

● Session:

Poster display session

● Presenter:

Kathleen N. Moore, M.D. (Omaha, United States)

● Date:

Thursday, June 18, 2026

● Location:

Exhibition

“Presenting this Trial-in-Progress poster at the ESMO

Gynaecological Cancers Congress places our ongoing Phase 2 study before the most focused and relevant audience for gynecologic oncology

in the U.S. and Europe,” said Thomas Jensen, Chief Executive Officer of Allarity Therapeutics. “For Allarity, this is an important

opportunity to highlight the clinical rationale and design of our stenoparib study, while beginning to frame the potential role our drug-specific

DRP® patient selection approach may play in addressing advanced platinum-resistant or platinum-ineligible ovarian cancer for this

highly specialized audience. Across both Europe and the U.S., this patient population is recognized as having an urgent need for new,

more tolerable treatment options. We are particularly pleased that the poster will be presented by our Principal Investigator, Dr. Kathleen

N. Moore, whose expertise in gynecologic oncology is widely recognized and highly valuable as we continue to advance stenoparib toward

its next clinical milestones.”

The poster will be available

on the Company’s website under the Scientific Publications section following its presentation on June 18, 2026.

Page 1 of 3

About Stenoparib/2X-121

Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. At present, tankyrases are attracting

significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the WNT signaling pathway.

Aberrant WNT/β-catenin signaling has been implicated in the development and progression of numerous cancers, especially drug-resistant

cancers. By inhibiting PARP and blocking WNT pathway activation, stenoparib’s unique therapeutic action shows potential as a promising

therapeutic for many cancer types, including ovarian cancer, small cell lung cancer and colorectal cancer. Allarity has secured exclusive

global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. and was formerly

known under the names E7449 and 2X-121. Allarity has completed its first Phase 2 trial for stenoparib in advanced ovarian cancer patients.

That trial showed promising and durable clinical benefit ovarian cancer patients who had 2+ lines of therapy were enrolled on stenoparib

and given drug twice daily. The updated data from this study were presented at the AACR special conference on advances in ovarian cancer

in September 2025. Note that, as these data are from an ongoing trial, analyses may change as the study fully matures. A new protocol

was designed expressly to capitalize on this emerging clinical experience with stenoparib in platinum resistant patients and began enrolling

patients in the summer of 2025. This amended protocol enrolls only platinum resistant or platinum-ineligible patients and is designed

to accelerate the clinical development of stenoparib toward FDA approval. In parallel, a separate Phase 2 trial evaluating stenoparib

in combination with temozolomide for relapsed small cell lung cancer (SCLC) began enrolling patients in early 2026 and is currently enrolling

patients across multiple VA sites in the US.

About the Drug Response Predictor – DRP® Companion Diagnostic

Allarity uses its drug-specific DRP® to select those

patients who, by the gene expression signature of their cancer, may have a high likelihood of benefiting from a specific drug. By screening

patients before treatment, and only treating those patients with a sufficiently high, drug-specific DRP score, the therapeutic benefit

rate may be enhanced. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic

information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes. DRP is based on messenger

RNA expression profiles from patient biopsies. The DRP® platform has shown an ability to provide a statistically significant prediction

of the clinical outcome from drug treatment in cancer patients across dozens of clinical studies (both retrospective and prospective).

The DRP platform, which may be useful in all cancer types and is patented for dozens of anti-cancer drugs, has been extensively published

in the peer-reviewed literature.

About Allarity Therapeutics

Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage

biopharmaceutical company dedicated to developing personalized cancer treatments. The Company is focused on development of stenoparib,

a novel PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP® technology to develop a companion diagnostic

that can be used to select those patients expected to derive the greatest clinical benefit from stenoparib. Allarity’s principal

operations are located in Denmark and its U.S. business address is in Florida and is committed to addressing significant unmet medical

needs in cancer treatment. For more information, visit www.allarity.com.

Follow Allarity on Social Media

LinkedIn: https://www.linkedin.com/company/allaritytx/

Page 2 of 3

Forward-Looking Statements

This press release contains “forward-looking statements”

within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company’s current

expectations or forecasts of future events. The words “anticipates,” “believe,” “continue,” “could,”

“estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,”

“potential,” “predicts,” “project,” “should,” “would” and similar expressions

may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking

statements include, but are not limited to, statements regarding the Company’s planned presentation of a Trial-in-Progress poster

at the ESMO Gynaecological Cancers Congress 2026; the expected availability of the poster on the Company’s website; the clinical

rationale, design, enrollment, conduct, and potential outcomes of the Company’s ongoing Phase 2 trial of stenoparib in advanced

platinum-resistant or platinum-ineligible ovarian cancer; the potential role of the Company’s drug-specific DRP® patient selection

approach; the potential clinical benefit, tolerability, and therapeutic profile of stenoparib; and the Company’s plans to advance

stenoparib toward future clinical, regulatory, and potential pivotal-development milestones. Any forward-looking statements in this press

release are based on management’s current expectations of future events and are subject to multiple risks and uncertainties that

could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These

risks and uncertainties include, but are not limited to, risks related to the timing or occurrence of the poster presentation; the availability

of the poster following presentation; the Company’s ability to conduct, enroll, and complete its ongoing and future clinical trials;

the possibility that prior clinical observations may not be confirmed in ongoing or future studies; the ability of stenoparib to demonstrate

sufficient safety, efficacy, tolerability, or clinical benefit to support further development or regulatory approval; the potential utility

and regulatory acceptance of the DRP® companion diagnostic strategy; the Company’s ability to obtain regulatory agreement on

future clinical development plans; and the Company’s ability to secure sufficient financial, operational, manufacturing, and clinical

resources to continue development of stenoparib. For a discussion of other risks and uncertainties, and other important factors, any of

which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk

Factors” in our Form 10-K annual report filed with the Securities and Exchange Commission (the “SEC”) on March 30, 2026,

and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 15, 2026, available at the SEC’s

website at www.sec.gov, as well as discussions of potential risks, uncertainties and other important factors in the Company’s subsequent

filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update

this information unless required by law.

###

Company Contact:

investorrelations@allarity.com

Media Contact:

Thomas Pedersen

Carrotize PR & Communications

+45 6062 9390

tsp@carrotize.com

Page 3 of 3

GRAPHIC

Filename: ea029540901_ex99-1img1.jpg · Sequence: 3

Binary file (9196 bytes)

Download ea029540901_ex99-1img1.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Jun. 18, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jun. 18, 2026

Entity File Number

001-41160

Entity Registrant Name

ALLARITY THERAPEUTICS, INC.

Entity Central Index Key

0001860657

Entity Tax Identification Number

87-2147982

Entity Incorporation, State or Country Code

Entity Address, Address Line One

123 E Tarpon Ave

Entity Address, City or Town

Tarpon Springs

Entity Address, State or Province

Entity Address, Postal Zip Code

34689

City Area Code

401

Local Phone Number

426-4664

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.0001 per share

Trading Symbol

ALLR

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration